(NASDAQ:EVAX)  AMERICAN DEPOSITORY SHARE: up more than 40% in pr-market trading this morning on news of successful cancer trial.

(NASDAQ:EVAX)  AMERICAN DEPOSITORY SHARE: up more than 40% in pr-market trading this morning on news of successful cancer trial.

Evaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies in Phase 1/2a Clinical Trial for EVX-02

OMX   “GlobeNewswire – EU Press Releases”

COPENHAGEN, Denmark, May 10, 2022 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ:EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today that it has successfully produced all batches of personalized cancer immunotherapies for all patients enrolled in the Phase 1/2a clinical trial of EVX-02 in adjuvant melanoma.

Read entire article: https://www.globenewswire.com/news-release/2022/05/10/2439615/0/en/Evaxion-Biotech-Announces-Successful-Production-of-Personalized-Cancer-Immunotherapies-in-Phase-1-2a-Clinical-Trial-for-EVX-02.html

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.